H.C. Wainwright analyst Andres Maldonado assumed coverage of Aura Biosciences (AURA) with a Buy rating and $22 price target Aura is advancing a tumor-targeted platform that combines localized cytotoxicity with systemic immune activation, anchored by its proprietary virus-like drug conjugate technology, the analyst tells investors in a research note. The firm says the company is positioned to redefine the treatment paradigm in ocular oncology, where early intervention is often avoided due to the destructive nature of existing therapies.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AURA:
- Strategic Positioning and Regulatory Advantage Bolster Aura Biosciences Inc’s Buy Rating
- Promising Developments and Strategic Advancements Propel Aura Biosciences Inc’s Buy Rating
- Aura Biosciences Advances in Cancer Therapy Trials
- Aura Biosciences Raises $69.9 Million in Public Offering
- Aura Biosciences: Strategic Advancements and Clinical Progress Drive Buy Rating